Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).
Haoran Li(General Hospital of Shenyang Military Region), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Sadia Saleem(The University of Texas Southwestern Medical Center), Ulka N. Vaishampayan(University of Michigan), D. Scott Ernst, Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Neeraj Agarwal(University of Utah), Reuben Broom(Auckland City Hospital), Jennifer J. Knox(National Cancer Center), Sun Young Rha(Yonsei University)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k